PL
AVIR icon

Parkwood LLC’s Atea Pharmaceuticals AVIR Stock Holding History

Parkwood LLC’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-71,932
Closed -$643K – 131
2021
Q4 		$643K Buy
+71,932
New +$1.12M 0.11% 85
2021
Q2 		– Sell
-8,341
Closed -$515K – 120
2021
Q1 		$515K Buy
+8,341
New +$564K 0.09% 94

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Parkwood LLC's AVIR Position: Q1 2022 in Review

Parkwood LLC sold out of Atea Pharmaceuticals (AVIR) in Q1 2022, closing a stake of 71,932 shares — an estimated $643K sold.

Parkwood LLC first reported a position in AVIR in Q1 2021 and held it in 2 quarters. The position peaked at $643K in Q4 2021. 127 funds tracked by Wall St. Rank hold AVIR as of Q1 2022.

  • Parkwood LLC reported no remaining Atea Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Parkwood LLC sold 71,932 Atea Pharmaceuticals shares in Q1 2022, an estimated $643K.
  • Parkwood LLC first reported a position in Atea Pharmaceuticals in Q1 2021 and held it in 2 quarters.
  • Parkwood LLC's Atea Pharmaceuticals position peaked at $643K in Q4 2021.
  • 127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2022.

Based on Parkwood LLC's 13F filing for Q1 2022, filed 13 May 2022.